News for Pluristem Therapeutics Inc. - Google Finance

PLURISTEM THERAPEUTICS INC. : Preclinical Research Shows PLX Cells May ...

Mon, 13 May 2013 16:04:54 GMT

PLURISTEM THERAPEUTICS INC. : Preclinical Research Shows PLX Cells May ...
4-traders (press release) - May 13, 2013

HAIFA, Israel May 13, 2013 - Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today its PLacental eXpanded (PLX) cells tested in preclinical animal models of preeclampsia ...

PLURISTEM THERAPEUTICS INC. : Pluristem and United Therapeutics Enter ...

Tue, 07 May 2013 15:06:47 GMT

PLURISTEM THERAPEUTICS INC. : Pluristem and United Therapeutics Enter ...
4-traders (press release) - May 7, 2013

Pluristem Therapeutics Inc. : Pluristem and United Therapeutics Enter into an Exclusive License Agreement to Develop and Commercialize PLX Cells for the Treatment of Pulmonary Hypertension.

Pluristem Develops PLX-RAD Cells for Use in Hematology - GlobeNewswire (press release)

PLURISTEM THERAPEUTICS INC. : Pluristem's PLX-PAD Cells' Safety in ...

Mon, 29 Apr 2013 07:26:56 GMT

PLURISTEM THERAPEUTICS INC. : Pluristem's PLX-PAD Cells' Safety in ...
4-traders (press release) - Apr 29, 2013

HAIFA, Israel April 29, 2013 - Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that independent researchers from the Queensland Lung Transplant Service at the University ...

Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in ... - GlobeNewswire (press release)

Stocks to Eyes On: Lumber Liquidators, Pluristem Therapeutics, Vocus, Unisys

Wed, 24 Apr 2013 16:52:52 GMT

Stocks to Eyes On: Lumber Liquidators, Pluristem Therapeutics, Vocus, Unisys
SBWire (press release) - Apr 24, 2013

Pluristem Therapeutics Inc. (NASDAQ:PSTI) moved up 5.26% to $3.08 on a traded volume of 11k shares. The Company is expanding its presence in the orthopedic and sports medicine markets with plans to initiate a Phase I clinical trial to evaluate the ...

Top Insider Purchases: APA, AIG, CVRR, LPSN, OPK, PSTI

Tue, 21 May 2013 15:14:33 GMT

Top Insider Purchases: APA, AIG, CVRR, LPSN, OPK, PSTI
iStockAnalyst (press release) - 1 hour ago

Pluristem Therapeutics Inc. (NASDAQ: PSTI): Director Ben-Yoram Israel bought a total of 63,902 shares between May 16 and May 20 at an average price of $3.04 for a total value of $194,206.

A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013

Mon, 20 May 2013 15:39:49 GMT

A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013
Seeking Alpha - May 20, 2013

My first recap company is Pluristem Therapeutics, Inc. (PSTI) which recently reported on its progress of its Phase I/II trial for the treatment of muscle injury utilizing PLX cells.

Pluristem to Present at Needham Healthcare and Oppenheimer Israeli ...

Tue, 30 Apr 2013 07:08:47 GMT

Pluristem to Present at Needham Healthcare and Oppenheimer Israeli ...
Wall Street Journal (press release) - Apr 30, 2013

HAIFA, Israel, April 30, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the company is scheduled to participate in the following investment ...

Preclinical study shows PLX cells may help reverse symptoms associated with ...

Fri, 17 May 2013 06:38:57 GMT

Preclinical study shows PLX cells may help reverse symptoms associated with ...
News-Medical.net - May 17, 2013

The PLX cells were created and patented by Israeli-based Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapies.

Position Yourself for Big Returns in the Stem Cell Space: Jason Kolbert

Mon, 13 May 2013 13:10:29 GMT

Position Yourself for Big Returns in the Stem Cell Space: Jason Kolbert
Trefis - May 13, 2013

If we compare what Osiris Therapeutics Inc. (OSIR:NASDAQ), Athersys Inc. (ATHX:NASDAQ), Pluristem Therapeutics Inc. (PSTI:NASDAQ) and Mesoblast are doing, they all have different variations of an allogeneic product (using cells from the same species).

Judge gives onetime 'King of Biotech' 4 years in prison

Thu, 02 May 2013 21:39:43 GMT

Judge gives onetime 'King of Biotech' 4 years in prison
Yahoo! News - May 2, 2013

David Blech, 57, pleaded guilty in May 2012 to securities fraud charges stemming from improper trades in biopharmaceutical companies Pluristem Therapeutics Inc and Intellect Neurosciences Inc. Blech pleaded guilty in 1998 to similar charges of illegal ...

NY biotech financier gets prison for stock scheme - Wall Street Journal